| | Hydroxychloroquine (EC50 = 0.72 M) were shown to be more effective than chloroquine (EC50 = 5.47 M) in in vitro. Based on the results of PBPK (Physiologically-based pharmacokinetic) models, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg twice daily for four days, is recommended for SARS-CoV-2 infection, as it reached three times the potency of chloroquine phosphate when given 500 mg twice daily five days in advance. | ✍ | 32150618
(Clin Infect Dis)
| PMID | 32150618 Date of Publishing: 2020 Jul 28 | | Title | In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | | Author(s) name | Yao X, Ye F et al. | | Journal | Clin Infect Dis | | Impact factor | 7.71 Citation count: 1245 | | Date of Entry | 2022 Jun 20 |
×
| NLM format |
| Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Jul 28;71(15):732-739. PMID:32150618 |
|